ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - sulphamethoxazole; trimethoprim - תמיסה לאינפוזיה - sulphamethoxazole 400 mg / 5 ml; trimethoprim 80 mg / 5 ml - sulfamethoxazole and trimethoprim - sulfamethoxazole and trimethoprim - bacterial infections of respiratory tract, gastrointestinal tracts and skin, susceptible to the drug.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - ofloxacin - קפליות - ofloxacin 200 mg - ofloxacin - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as: upper and lower urinary tract infections, lower respiratory tract infections uncomplicated urethral and cervical gonorrhoea, non-gonococcal urethritis and cervicitis, skin and soft tissue infections.

ישראל - עברית - Ministry of Health

rekah pharmaceutical industry - isoniazid 50 mg - tablets - isoniazid - antibacterial, tubercolistic.

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - benzocaine; neomycin as sulfate; phenylephrine hydrochloride; sodium propionate - טיפות - benzocaine 3 %; neomycin as sulfate 0.35 %; phenylephrine hydrochloride 0.25 %; sodium propionate 5 % - antiinfectives, combinations - antiinfectives, combinations - antibacterial, antifungal ear drops.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); pertactin; pertussis toxoid (pt); tetanus toxoid - תרחיף להזרקה - diphtheria toxoid nlt 30 iu; tetanus toxoid nlt 40 iu; pertactin 8 mcg / 0.5 ml; filamentous haemagglutinin (fha) 25 mcg / 0.5 ml; pertussis toxoid (pt) 25 mcg / 0.5 ml - bacterial and viral vaccines, combined - infanrix is indicated as a booster dose for children 15 months to 7 years of age who have previously been immunised with three or four doses of either dtpa vaccine or diphtheria, tetanus and whole-cell pertussis (dtpw) vaccine. active primary immunisation against diphteria, tetanus and pertussis from the age 2 months onward.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); haemophilus b; hepatitis b vaccines; pertactin; pertussis toxoid (pt); poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated; tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - filamentous haemagglutinin (fha) 25 mcg/dose; diphtheria toxoid nlt 30 iu/dose; tetanus toxoid nlt 40 iu/dose; hepatitis b vaccines 10 mcg/dose; poliovirus type 1 inactivated 40 du/dose; poliovirus type 2 inactivated 8 du/dose; poliovirus type 3 inactivated 32 du/dose; haemophilus b 10 mcg/dose; pertactin 8 mcg/dose; pertussis toxoid (pt) 25 mcg/dose - bacterial and viral vaccines, combined - infantix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenza type b.

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - ceftazidime as pentahydrate - אבקה להמסה להזרקה\אינפוזיה - ceftazidime as pentahydrate 1000 mg - third generation cephalosporins - bacterial infections due to susceptible micro-organisms.

ישראל - עברית - Ministry of Health

bioavenir ltd, israel - ceftazidime as pentahydrate - אבקה להמסה להזרקה\אינפוזיה - ceftazidime as pentahydrate 2000 mg/vial - third generation cephalosporins - bacterial infections due to susceptible micro-organisms.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid 30 iu / 0.5 ml; filamentous haemogglutinin (fha) 25 mcg / 0.5 ml - suspension for injection - bacterial and viral vaccines, combined - this vaccine is indicated for booster vaccination against diphtheria, tetanus , pertussis, and poliomyelitis diseases in individuals from 16 months to 13 years of age inclusive.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - hpv-16 l1; hpv-18 l1 - תרחיף להזרקה - hpv-18 l1 20 mcg / 0.5 ml; hpv-16 l1 20 mcg / 0.5 ml - bacterial and viral vaccines, combined - cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic human papillomavirus (hpv) types.